First Tracks Biotherapeutics, Inc.: stock overview

TRAXNASDAQHealthcare · Pharmaceutical PreparationsNew listingsince Apr 1, 2026

Price

$41.64

November 20, 2026Market cap $1.7B

New listing: quarterly reports only so far

The first annual report (10-K) is expected around March 31, 2027; valuation and multi-year figures start then.

In short

First Tracks Biotherapeutics has been listed since April 1, 2026. In the quarter to September 30, 2026 it reported no revenue and a net loss of $31M. On September 30, 2026 it held $156M of cash.

Figures from the quarterly reports (10-Q) to the quarter ended September 30, 2026; price as of November 20, 2026.

Latest 10-Q
Market cap
$1.7B
42.02M shares
Revenue, quarter
–
to Sep 30, 2026
Net income, quarter
-$31M
to Sep 30, 2026
Cash
$156M
on Sep 30, 2026

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

The quarters it has reported

Each quarter as its 10-Q reports it, beside the same quarter a year earlier, which the same report gives for comparison.

3 quarters
  • Sep 30, 2026to Sep 30, 2026
    Change–
  • Jun 30, 2026to Jun 30, 2026
    Change–
  • Mar 31, 2026to Mar 31, 2026
    Change–

Earnings per share for quarters before the listing divide by the fewer shares there were then, so they do not compare directly with today's.

Balance sheet

From the latest 10-Q, beside the end of the previous fiscal year, which the same report gives for comparison.

LineSep 30, 2026Dec 31, 2025
Total assets$170M$331M
Cash and equivalents$156M$238M
Total debt––
Shareholders' equity$151M$287M

The company at the SEC

How it is registered and when its fiscal year ends.

First annual report
around March 31, 2027
Name at the SEC
First Tracks Biotherapeutics, Inc.
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Shares
42.02M, 10-Q cover, Oct 29, 2026

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.